Pimavanserin To Make Massive Revenue in Multiple Applications. Article.
Great Article Explains Potential of ACAD.
Seeking Alpha By: Scott Matusow ARTICLE : Obagi Medical Products Acquired Wednesday, These Biotechs May Be Next
Acadia has drug candidates for the treatment of Parkinson's disease, Alzheimer's, schizophrenia, and glaucoma. These conditions are all connected with large market size and present significant opportunities for big pharma. Acadia has shown ability in the past to partner or collaborate with larger companies such as Biovail, Allergan, and Meija Seika Kaisha, LTD. It is not being overly presumptive to assume that big pharmawould have interest in Acadia for its lead drug pimavanserin, which possesses potential for massive revenue in multiple applications.